Salvage treatment in metastatic breast cancer with weekly paclitaxel and bevacizumab

Background Weekly paclitaxel (P) in combination with bevacizumab (B) is an effective regimen as initial treatment of metastatic breast cancer (MBC). We investigated in a phase II study the activity of the same regimen as salvage therapy in MBC. Methods Pretreated women with MBC received weekly P (90 mg/m 2 days 1, 8, 15) and B (10 mg/kg days 1, 15) every 28 days. B could continue after discontinuing P until disease progression. This was second-line chemotherapy for 30% and third-line or more for 70% of patients. Results A total of 40 patients were enrolled. Median age: 61 (range 32–80) years; postmenopausal: 80%; baseline ECOG performance status